O	0	1	A
O	2	12	Randomized
O	12	13	,
O	14	20	Single
O	20	21	-
O	21	26	Blind
O	27	32	Study
O	33	43	Evaluating
O	44	47	the
O	48	54	Effect
O	55	57	of
O	58	59	a
B-intervention	60	64	Bone
I-intervention	65	69	Pain
I-intervention	70	79	Education
I-intervention	80	85	Video
O	86	88	on
O	89	97	Reported
B-condition	98	102	Bone
I-condition	103	107	Pain
O	108	110	in
O	111	119	Patients
O	120	124	with
O	125	131	Breast
O	132	138	Cancer
O	139	148	Receiving
O	149	161	Chemotherapy
O	162	165	and
O	166	179	Pegfilgrastim
O	179	180	.

O	181	185	Mild
O	185	186	-
O	186	188	to
O	188	189	-
O	189	197	moderate
O	198	202	bone
O	203	207	pain
O	208	210	is
O	211	214	the
O	215	219	most
O	220	228	commonly
O	229	237	reported
O	238	245	adverse
O	246	251	event
O	252	262	associated
O	263	267	with
O	268	281	pegfilgrastim
O	281	282	.

O	283	285	To
O	286	297	investigate
O	298	301	the
O	302	308	effect
O	309	311	of
O	312	316	bone
O	317	321	pain
O	322	331	education
O	332	334	on
O	335	348	pegfilgrastim
O	348	349	-
O	349	356	related
O	357	361	bone
O	362	366	pain
O	367	369	in
O	370	378	patients
O	379	383	with
O	384	390	breast
O	391	397	cancer
O	398	407	receiving
O	408	420	chemotherapy
O	421	424	and
O	425	438	pegfilgrastim
O	438	439	.

O	440	450	Randomized
O	450	451	,
O	452	458	single
O	458	459	-
O	459	464	blind
O	465	470	study
O	470	471	.

O	472	477	Forty
O	477	478	-
O	478	483	eight
O	484	493	community
O	494	502	oncology
O	503	510	clinics
O	511	521	throughout
O	522	525	the
B-location	526	532	United
I-location	533	539	States
O	539	540	.

B-total-participants	541	546	Three
I-total-participants	547	554	hundred
O	555	560	women
B-age	561	562	≥
I-age	562	564	18
I-age	565	570	years
O	571	573	of
O	574	577	age
B-eligibility	578	582	with
I-eligibility	583	588	newly
I-eligibility	589	598	diagnosed
I-eligibility	599	604	stage
I-eligibility	605	606	I
I-eligibility	607	608	-
I-eligibility	608	611	III
I-eligibility	612	618	breast
I-eligibility	619	625	cancer
I-eligibility	625	626	,
I-eligibility	627	630	who
I-eligibility	631	635	were
I-eligibility	636	644	planning
I-eligibility	645	646	≥
I-eligibility	646	647	4
I-eligibility	648	654	cycles
I-eligibility	655	657	of
I-eligibility	658	669	neoadjuvant
I-eligibility	670	672	or
I-eligibility	673	681	adjuvant
I-eligibility	682	694	chemotherapy
I-eligibility	695	699	with
I-eligibility	700	713	pegfilgrastim
I-eligibility	714	721	support
I-eligibility	722	730	starting
I-eligibility	731	733	in
I-eligibility	734	739	cycle
I-eligibility	740	741	1
O	741	742	.

O	743	751	Patients
O	752	756	were
O	757	767	randomized
O	768	769	1
O	769	770	:
O	770	771	1
O	772	774	to
O	775	779	view
O	780	781	a
B-control	782	789	general
I-control	790	799	education
I-control	800	803	DVD
O	804	806	on
O	807	819	chemotherapy
O	820	824	side
O	825	832	effects
O	833	834	(
O	834	836	GE
O	836	837	-
O	837	840	DVD
O	840	841	)
O	842	844	or
O	845	846	a
O	847	850	DVD
O	851	853	on
O	854	858	bone
O	859	863	pain
O	864	873	following
O	874	886	chemotherapy
O	887	890	and
O	891	904	pegfilgrastim
O	905	906	(
O	906	908	BP
O	908	909	-
O	909	912	DVD
O	912	913	)
O	913	914	.

O	915	923	Patients
O	924	932	recorded
O	933	941	severity
O	942	944	of
O	945	949	bone
O	950	954	pain
O	955	957	on
O	958	959	a
O	960	965	scale
O	966	968	of
O	969	970	0
O	970	971	-
O	971	973	10
O	973	974	,
O	975	983	location
O	984	986	of
O	987	991	pain
O	991	992	,
O	993	996	and
O	997	1000	use
O	1001	1003	of
O	1004	1008	bone
O	1009	1013	pain
O	1014	1025	medications
O	1026	1027	(
O	1027	1028	i
O	1028	1029	.
O	1029	1030	e
O	1030	1031	.
O	1031	1032	,
O	1033	1043	analgesics
O	1043	1044	,
O	1045	1059	antihistamines
O	1059	1060	,
O	1061	1064	and
O	1065	1077	nonsteroidal
O	1078	1082	anti
O	1082	1083	-
O	1083	1095	inflammatory
O	1096	1101	drugs
O	1101	1102	)
O	1103	1106	for
O	1107	1108	5
O	1109	1113	days
O	1113	1114	,
O	1115	1124	beginning
O	1125	1127	on
O	1128	1131	the
O	1132	1135	day
O	1136	1138	of
O	1139	1152	pegfilgrastim
O	1153	1167	administration
O	1167	1168	,
O	1169	1171	in
O	1172	1176	each
O	1177	1179	of
O	1180	1183	the
O	1184	1189	first
O	1190	1194	four
O	1195	1207	chemotherapy
O	1208	1214	cycles
O	1214	1215	.

B-outcome	1216	1223	Patient
I-outcome	1223	1224	-
I-outcome	1224	1232	reported
I-outcome	1233	1240	maximum
I-outcome	1241	1245	bone
I-outcome	1246	1250	pain
O	1251	1254	was
O	1255	1262	similar
O	1263	1265	in
O	1266	1269	the
O	1270	1273	two
O	1274	1280	groups
O	1281	1282	(
O	1282	1284	GE
O	1284	1285	-
O	1285	1288	DVD
O	1289	1291	vs
O	1292	1294	BP
O	1294	1295	-
O	1295	1298	DVD
O	1298	1299	:
O	1300	1305	cycle
O	1306	1307	1
O	1307	1308	,
B-cv-cont-mean	1309	1310	3
I-cv-cont-mean	1310	1311	.
I-cv-cont-mean	1311	1312	2
O	1313	1315	vs
O	1315	1316	.
B-iv-cont-mean	1317	1318	3
I-iv-cont-mean	1318	1319	.
I-iv-cont-mean	1319	1320	5
O	1320	1321	,
O	1322	1323	p
O	1324	1325	=
O	1326	1327	.
O	1327	1331	3479
O	1331	1332	;
O	1333	1339	across
O	1340	1343	all
O	1344	1350	cycles
O	1350	1351	,
O	1352	1353	4
O	1353	1354	.
O	1354	1355	1
O	1356	1358	vs
O	1358	1359	.
O	1360	1361	4
O	1361	1362	.
O	1362	1363	6
O	1363	1364	,
O	1365	1366	p
O	1367	1368	=
O	1369	1370	.
O	1370	1374	2196
O	1374	1375	)
O	1375	1376	.

O	1377	1382	Other
B-outcome	1383	1391	measures
I-outcome	1392	1394	of
I-outcome	1395	1399	bone
I-outcome	1400	1404	pain
O	1405	1409	were
O	1410	1414	also
O	1415	1422	similar
O	1423	1430	between
O	1431	1434	the
O	1435	1441	groups
O	1441	1442	.

B-outcome	1443	1447	Bone
I-outcome	1448	1452	pain
O	1453	1456	was
O	1457	1464	highest
O	1465	1467	in
O	1468	1473	cycle
O	1474	1475	1
O	1476	1479	but
O	1480	1489	decreased
O	1490	1493	and
O	1494	1498	then
O	1499	1507	remained
O	1508	1514	stable
O	1515	1517	in
O	1518	1528	subsequent
O	1529	1535	cycles
O	1535	1536	.

B-outcome	1537	1541	Bone
I-outcome	1542	1546	pain
I-outcome	1547	1557	medication
I-outcome	1558	1561	use
O	1562	1565	was
O	1566	1573	similar
O	1574	1576	in
O	1577	1581	both
O	1582	1588	groups
O	1589	1592	and
O	1593	1596	was
O	1597	1604	highest
O	1605	1607	in
O	1608	1613	cycle
O	1614	1615	1
O	1615	1616	.

O	1617	1620	The
O	1621	1625	bone
O	1626	1630	pain
O	1630	1631	-
O	1631	1639	specific
O	1640	1649	education
O	1650	1659	evaluated
O	1660	1664	here
O	1665	1668	did
O	1669	1672	not
O	1673	1680	improve
O	1681	1692	perceptions
O	1693	1695	of
O	1696	1700	bone
O	1701	1705	pain
O	1706	1714	reported
O	1715	1717	in
O	1718	1722	this
O	1723	1730	patient
O	1731	1741	population
O	1741	1742	.
